XTX Topco Ltd lowered its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 54.6% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 25,577 shares of the company's stock after selling 30,783 shares during the quarter. XTX Topco Ltd's holdings in Cellebrite DI were worth $563,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also made changes to their positions in CLBT. Juncture Wealth Strategies LLC increased its position in Cellebrite DI by 0.8% during the fourth quarter. Juncture Wealth Strategies LLC now owns 60,003 shares of the company's stock worth $1,322,000 after buying an additional 505 shares in the last quarter. Strategic Advisors LLC lifted its stake in shares of Cellebrite DI by 3.4% during the fourth quarter. Strategic Advisors LLC now owns 29,082 shares of the company's stock valued at $641,000 after buying an additional 950 shares during the period. Steward Partners Investment Advisory LLC boosted its position in Cellebrite DI by 12.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 13,590 shares of the company's stock worth $299,000 after acquiring an additional 1,463 shares during the last quarter. Tower View Wealth Management LLC grew its stake in Cellebrite DI by 1.3% in the 4th quarter. Tower View Wealth Management LLC now owns 132,307 shares of the company's stock worth $2,915,000 after acquiring an additional 1,660 shares during the period. Finally, Meritage Portfolio Management raised its holdings in Cellebrite DI by 7.4% in the 4th quarter. Meritage Portfolio Management now owns 29,901 shares of the company's stock valued at $659,000 after acquiring an additional 2,070 shares during the last quarter. Hedge funds and other institutional investors own 45.88% of the company's stock.
Wall Street Analyst Weigh In
A number of analysts have issued reports on the company. Needham & Company LLC reissued a "buy" rating and issued a $28.00 price target on shares of Cellebrite DI in a research note on Wednesday, April 2nd. JPMorgan Chase & Co. increased their price target on shares of Cellebrite DI from $24.00 to $28.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 11th. Finally, Lake Street Capital upped their price objective on Cellebrite DI from $17.00 to $26.00 and gave the stock a "buy" rating in a report on Friday, February 14th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $23.43.
Check Out Our Latest Analysis on Cellebrite DI
Cellebrite DI Trading Down 0.5 %
NASDAQ CLBT traded down $0.09 during trading hours on Friday, reaching $19.47. The company's stock had a trading volume of 120,914 shares, compared to its average volume of 1,406,219. The stock has a market cap of $4.66 billion, a PE ratio of -13.98, a PEG ratio of 4.27 and a beta of 1.44. The business has a 50-day simple moving average of $18.75 and a 200 day simple moving average of $20.10. Cellebrite DI Ltd. has a 52 week low of $10.25 and a 52 week high of $26.30.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. As a group, equities analysts predict that Cellebrite DI Ltd. will post 0.3 EPS for the current year.
About Cellebrite DI
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Featured Articles
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
